Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Osteoporosis
•
Primary Care
Would you use anabolic agents (romosozumab or PTH analogues) for osteoporosis treatment in patients with CKD?
Related Questions
Would you have concerns about combining romosuzumab and IVIG in a patient with dermatomyositis and osteoporosis?
What is your experience with using anabolic therapy for treatment of osteoporosis in patients with EtOH cirrhosis and is one agent preferred over another (PTH analogue vs Evenity)?
Would you have concerns with continuing denosumab for much longer than the available ten year clinical safety trial data for an individual with renal insufficiency with persistent osteoporosis/history of compression fractures?
Would you consider PTH analogue in a patient with mildly elevated PTH?
Would you order a repeat DEXA scan 1 year later for a kidney transplant patient who had an initial DEXA scan within the first 6 months post-transplant showing osteopenia but no history of fractures, and who has been stable on glucocorticoid-free immunosuppressive therapy?
When do you recommend using trabecular bone score (TBS) for managing osteoporosis?
Can you use bisphosphonates in a patient with osteoporosis who has had prior avascular necrosis of TMJ due to steroid use?
How would you approach a patient with osteoporosis who remains at risk for osteoporotic fracture and who had an atypical femur fracture on denosumab?
Would you consider using Evenity in an elderly patient with rate controlled atrial fibrillation without history of MI or CVA?
How frequently do you monitor for hypocalcemia in patients on romosozumab?
